Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read More
Mark Eckert, PhDUniversity of Chicago Targeting T-LAK cell-originated protein kinase (TOPK) for ovarian cancer therapy Ovarian cancer is one of the most lethal cancers due to a lack of effective therapies. Dr. Eckert’s lab recently found that the protein T-LAK cell-originated protein kinase (TOPK) is expressed in ovarian cancer cells, but not most normal tissues. […]
Read More
Melissa Merritt, PhDUniversity of Hawaii Cancer Center Obesity-related factors and ovarian cancer survival Women diagnosed with ovarian cancer have a poor prognosis, and there are currently no recommendations for lifestyle modifications that may influence survival after a diagnosis. Dr. Merritt will evaluate whether obesity-related factors, including Body Mass Index (BMI), waist circumference, physical activity, and […]
Read More
Yael Raz Yana, MDCedars-Sinai Medical Center 2019 Cookie Laughlin Scholar Award Studying the Fallopian Tubes of BRCA Mutation Carriers to Understand the Infrastructure for Malignant Transformation Though the majority of ovarian cancer patients are postmenopausal, it is unknown how age and postmenopausal conditions contribute to cancer development. Women with inherited BRCA1 gene mutations are at […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More
Cheng Wang, PhDUniversity of Nebraska Medical Center2015 Barbara Learned Bridge Funding Award The Hippo/YAP Signaling Pathway in Ovarian High Grade Serous Carcinoma Knowing where and how ovarian cancer starts will lead to earlier detection and better therapies. Recent studies have identified the fallopian tube secretory epithelial cell as the origin for high-grade serous ovarian carcinoma, […]
Read More
Paul Campagnola, PhDUniversity of Wisconsin – Madison2015 Joanie Warner Bridge Funding Award Quantitative Assessment of the Role of Collagen Alterations in Ovarian Cancer High grade serous ovarian cancer arises from fallopian tube cells that migrate and implant on the ovaries, then subsequently metastasize to other sites in the body. The 3-dimensional composition and architecture of […]
Read More
Bo Yu, MDUniversity of Washington2017 Cookie Laughlin Bridge Funding Award The role of fallopian tube microbiome in ovarian carcinogenesis Ovarian cancer is the most lethal gynecological cancer in the United States. The high mortality rate is due to a lack of understanding of the origin and development of this disease, which makes both early detection […]
Read More
Adam Karpf, PhDUniversity of Nebraska Medical Center2018 Kirwin-Hinton Bridge Funding Award Rhno1 in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer (HGSOC) is the most common and deadly form of ovarian cancer, accounting for about 25,000 cases and 15,000 deaths in the United States every year. New and improved therapies are critically needed for HGSOC. […]
Read More
Elizabeth Smith, PhDFox Chase Cancer Center Suppression of cyclooxygenase in prevention of menopausal gonadotropin-stimulated ovarian cancer risk The risk of developing ovarian cancer increases rapidly in the peri- and post-menopausal periods, when ovulation ceases but the reproductive gonadotropin hormones are elevated. These gonadotropins can induce expression of certain enzymes which stimulate an inflammation-like condition that […]
Read More